Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma.

Anilides / pharmacology Antineoplastic Combined Chemotherapy Protocols / pharmacology Carcinoma, Renal Cell / drug therapy Cell Line, Tumor Dasatinib / pharmacology Humans Kidney Neoplasms / drug therapy Protein Kinase Inhibitors / administration & dosage Pyridines / pharmacology Signal Transduction / drug effects src-Family Kinases / metabolism
MEK SRC VEGFR cabozantinib cobimetinib combination therapies dasatinib high throughput screen kidney cancer non-clear cell renal cell carcinoma

Journal

Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894

Informations de publication

Date de publication:
18 05 2021
Historique:
received: 29 07 2020
revised: 18 01 2021
accepted: 13 04 2021
entrez: 7 6 2021
pubmed: 8 6 2021
medline: 8 6 2021
Statut: epublish

Résumé

The lack of effective treatment options for advanced non-clear cell renal cell carcinoma (NCCRCC) is a critical unmet clinical need. Applying a high-throughput drug screen to multiple human kidney cancer cells, we identify the combination of the VEGFR-MET inhibitor cabozantinib and the SRC inhibitor dasatinib acts synergistically in cells to markedly reduce cell viability. Importantly, the combination is well tolerated and causes tumor regression

Identifiants

DOI: 10.1016/j.xcrm.2021.100267 PMID: 34095877 PMC: PMC8149375
pubmed: 34095877
doi: 10.1016/j.xcrm.2021.100267
pii: S2666-3791(21)00089-6
pmc: PMC8149375
doi:

Substances chimiques

Anilides 0
Protein Kinase Inhibitors 0
Pyridines 0
cabozantinib 1C39JW444G
src-Family Kinases EC 2.7.10.2
Dasatinib RBZ1571X5H

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Pagination

100267

Subventions

Organisme : NCI NIH HHS
ID : R01 CA169172
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA069533
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA069533
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA222455
Pays : United States
Organisme : NHGRI NIH HHS
ID : U54 HG008100
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008339
Pays : United States

Informations de copyright

© 2021 The Author(s).

Déclaration de conflit d'intérêts

The authors declare no competing interests.

Références

J Vis Exp. 2018 Aug 2;(138):
pubmed: 30124664
Eur Urol. 2016 May;69(5):866-74
pubmed: 26626617
N Engl J Med. 2016 Jan 14;374(2):135-45
pubmed: 26536169
Cancer Discov. 2017 Jul;7(7):750-765
pubmed: 28274958
J Clin Oncol. 2020 Jan 1;38(1):63-70
pubmed: 31721643
J Clin Oncol. 2013 Oct 20;31(30):3791-9
pubmed: 24019545
Drug Metab Dispos. 2016 Jan;44(1):28-39
pubmed: 26451002
Lancet Oncol. 2019 Apr;20(4):581-590
pubmed: 30827746
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Eur J Cancer. 2018 Nov;104:188-194
pubmed: 30380460
Mol Cancer Ther. 2011 Dec;10(12):2298-308
pubmed: 21926191
N Engl J Med. 2015 Nov 5;373(19):1814-23
pubmed: 26406150
Cell. 2016 Aug 11;166(4):1041-1054
pubmed: 27499020
J Am Soc Nephrol. 2003 Nov;14(11):2703-11
pubmed: 14569079
Cancer Res. 2015 May 15;75(10):2061-70
pubmed: 25836719
Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1643-8
pubmed: 22307624
Cancer Res. 2011 Jul 15;71(14):4758-68
pubmed: 21613405
J Cancer. 2016 Jun 18;7(10):1205-14
pubmed: 27390595
J Clin Oncol. 2017 Feb 20;35(6):591-597
pubmed: 28199818
Nat Genet. 2016 Aug;48(8):838-47
pubmed: 27322546
Clin Cancer Res. 2011 Jun 15;17(12):3943-55
pubmed: 21540237
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
Genome Biol. 2014;15(12):550
pubmed: 25516281
Cell Cycle. 2009 Apr 15;8(8):1168-75
pubmed: 19282669
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Sci Transl Med. 2011 Jun 1;3(85):85ra47
pubmed: 21632985
Br J Cancer. 2008 Oct 7;99(7):1074-82
pubmed: 18797457
Mol Cancer Ther. 2013 Dec;12(12):2864-73
pubmed: 24130049
J Natl Cancer Inst. 2014 Apr;106(4):dju033
pubmed: 24634505
Lancet Oncol. 2016 Mar;17(3):378-388
pubmed: 26794930
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Bioinformatics. 2004 Nov 22;20(17):3246-8
pubmed: 15180930
Bioinformatics. 2013 Nov 1;29(21):2757-64
pubmed: 23986566
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
J Pharmacol Exp Ther. 2017 Dec;363(3):428-443
pubmed: 29021381
Nat Biotechnol. 2009 Jul;27(7):659-66
pubmed: 19581876
J Clin Oncol. 2002 May 1;20(9):2376-81
pubmed: 11981011
Curr Treat Options Oncol. 2018 Jan 24;19(1):5
pubmed: 29368112
Cancer. 2011 May 15;117(10):2112-9
pubmed: 21523723
Cell Rep. 2018 Jun 19;23(12):3698
pubmed: 29925010
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
J Clin Oncol. 2010 Oct 20;28(30):4609-15
pubmed: 20855820
Cancer. 2013 Aug 15;119(16):2999-3006
pubmed: 23696129
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Int J Cancer. 2015 Apr 15;136(8):1967-75
pubmed: 25242168
PLoS One. 2013;8(3):e58262
pubmed: 23484006
Clin Cancer Res. 2011 Nov 1;17(21):6897-904
pubmed: 21903773
Genes Dev. 2017 Oct 15;31(20):2067-2084
pubmed: 29138276
Lancet. 2021 Feb 20;397(10275):695-703
pubmed: 33592176
Oncogene. 2016 May;35(21):2687-97
pubmed: 26364599
Front Cell Dev Biol. 2018 Jun 19;6:62
pubmed: 29971233
Eur J Cancer. 2020 Aug;135:203-210
pubmed: 32599410
Nucleic Acids Res. 2004 Jan 1;32(Database issue):D115-9
pubmed: 14681372
J Biomed Sci. 2006 Mar;13(2):205-13
pubmed: 16456711
Oncotarget. 2015 Dec 29;6(42):44675-87
pubmed: 26625308
Nat Med. 2017 Apr 7;23(4):405-408
pubmed: 28388612
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Bioinformatics. 2018 Jun 15;34(12):2150-2152
pubmed: 29420694
Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1
pubmed: 28410911
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
pubmed: 9843981
Gynecol Oncol. 2012 Oct;127(1):70-4
pubmed: 22710075
Ann Oncol. 2013 Jul;24(7):1730-1740
pubmed: 23625974
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Commun. 2020 Aug 27;11(1):4296
pubmed: 32855387
N Engl J Med. 2003 Jul 31;349(5):419-21
pubmed: 12890838
Clin Genitourin Cancer. 2019 Feb;17(1):46-57.e5
pubmed: 30391138
Clin Cancer Res. 2016 Feb 15;22(4):923-34
pubmed: 26432786
Cancer Biol Ther. 2017 Nov 2;18(11):863-871
pubmed: 27715452
Cancer. 2006 Dec 1;107(11):2617-21
pubmed: 17083126
N Engl J Med. 2017 Jan 26;376(4):354-366
pubmed: 28121507
Nature. 2012 Mar 28;483(7391):570-5
pubmed: 22460902
J Natl Compr Canc Netw. 2017 Jun;15(6):804-834
pubmed: 28596261
Lancet Oncol. 2016 Jul;17(7):917-927
pubmed: 27279544
Nat Rev Cancer. 2004 Jun;4(6):470-80
pubmed: 15170449
Adv Cancer Res. 2018;138:99-142
pubmed: 29551131
Clin Pharmacokinet. 2017 May;56(5):477-491
pubmed: 27734291

Auteurs

Hui-Wen Lue (HW)

Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.

Daniel S Derrick (DS)

Department of Biomedical Engineering, Oregon Health and Science University Center for Spatial Systems Biomedicine, Portland, OR, USA.

Soumya Rao (S)

Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.

Ahna Van Gaest (A)

Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.

Larry Cheng (L)

Graduate Program in Quantitative Biomedicine, Rutgers University, Piscataway, NJ, USA.

Jennifer Podolak (J)

Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.

Samantha Lawson (S)

Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.

Changhui Xue (C)

Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.

Devin Garg (D)

Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.

Ralph White (R)

Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA.

Christopher W Ryan (CW)

Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Division of Hematology and Oncology, Oregon Health and Science University, Portland, OR, USA.

Justin M Drake (JM)

Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA.
Department of Urology, University of Minnesota, Minneapolis, MN, USA.
Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.

Anna Ritz (A)

Department of Biology, Reed College, Portland, OR, USA.

Laura M Heiser (LM)

Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Department of Biomedical Engineering, Oregon Health and Science University Center for Spatial Systems Biomedicine, Portland, OR, USA.

George V Thomas (GV)

Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Department of Pathology and Laboratory Medicine, Oregon Health and Science University, Portland, OR, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés chimiques organiques › Amines › Dérivés de l'aniline › Anilides › Cabozantinib and dasatinib synergize to induce...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Cabozantinib and dasatinib synergize to induce...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › Néphrocarcinome › Cabozantinib and dasatinib synergize to induce...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Cabozantinib and dasatinib synergize to induce...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Dasatinib › Cabozantinib and dasatinib synergize to induce...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Cabozantinib and dasatinib synergize to induce...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › Cabozantinib and dasatinib synergize to induce...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Cabozantinib and dasatinib synergize to induce...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Cabozantinib and dasatinib synergize to induce...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Cabozantinib and dasatinib synergize to induce...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-tyrosine kinases › src-Family kinases › Cabozantinib and dasatinib synergize to induce...